• Je něco špatně v tomto záznamu ?

Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors

C. Lonati, A. Necchi, J. Gómez Rivas, L. Afferi, E. Laukhtina, A. Martini, E. Ventimiglia, R. Colombo, G. Gandaglia, A. Salonia, A. Briganti, F. Montorsi, A. Mattei, C. Simeone, MI. Carlo, SF. Shariat, PE. Spiess, M. Moschini, European...

. 2022 ; 5 (1) : 30-41. [pub] 20211209

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019425

CONTEXT: Upper tract urothelial carcinoma (UTUC) represents the third most frequent malignancy in Lynch syndrome (LS). OBJECTIVE: To systematically review the available literature focused on incidence, diagnosis, clinicopathological features, oncological outcomes, and screening protocols for UTUC among LS patients. EVIDENCE ACQUISITION: Medline, Scopus, Google Scholar, and Cochrane Database of Systematic Reviews were searched up to May 2021. Risk of bias was determined using the modified Cochrane tool. A narrative synthesis was undertaken. EVIDENCE SYNTHESIS: Overall, 43 studies between 1996 and 2020 were included. LS patients exhibited a 14-fold increased risk of UTUC compared with the general population, which further increased to 75-fold among hMSH2 mutation carriers. Patients younger than 65 yr and patients with personal or family history of LS-related cancers should be referred to molecular testing on tumour specimen and subsequent genetic testing to confirm LS. Newly diagnosed LS patients may benefit from a multidisciplinary management team including gastroenterologist and gynaecologist specialists, while genetic counselling should be recommended to first-degree relatives (FDRs). Compared with sporadic UTUC individuals, LS patients were significantly younger (p = 0.005) and exhibited a prevalent ureteral location (p = 0.01). Radical nephroureterectomy was performed in 75% of patients (5-yr cancer-specific survival: 91%). No consensus on screening protocols for UTUC was achieved: starting age varied between 25-35 and 50 yr, while urinary cytology showed sensitivity of 29% and was not recommended for screening. CONCLUSIONS: Urologists should recognise patients at high risk for LS and address them to a comprehensive diagnostic pathway, including molecular and genetic testing. Newly diagnosed LS patients should be referred to a multidisciplinary team, while genetic counselling should be recommended to FDRs. PATIENT SUMMARY: In this systematic review, we analysed the existing literature focused on upper tract urothelial carcinoma (UTUC) among patients with Lynch syndrome (LS). Our purpose is to provide a comprehensive overview of LS-related UTUC to reduce misdiagnosis and improve patient prognosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019425
003      
CZ-PrNML
005      
20220804135638.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euo.2021.11.001 $2 doi
035    __
$a (PubMed)34896051
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Lonati, Chiara $u Department of Urology, Spedali Civili di Brescia, Brescia, Italy; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. Electronic address: chiara.lonati@libero.it
245    10
$a Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors / $c C. Lonati, A. Necchi, J. Gómez Rivas, L. Afferi, E. Laukhtina, A. Martini, E. Ventimiglia, R. Colombo, G. Gandaglia, A. Salonia, A. Briganti, F. Montorsi, A. Mattei, C. Simeone, MI. Carlo, SF. Shariat, PE. Spiess, M. Moschini, European Association of Urology Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group, the Global Society of Rare Genitourinary Tumors GSRGT
520    9_
$a CONTEXT: Upper tract urothelial carcinoma (UTUC) represents the third most frequent malignancy in Lynch syndrome (LS). OBJECTIVE: To systematically review the available literature focused on incidence, diagnosis, clinicopathological features, oncological outcomes, and screening protocols for UTUC among LS patients. EVIDENCE ACQUISITION: Medline, Scopus, Google Scholar, and Cochrane Database of Systematic Reviews were searched up to May 2021. Risk of bias was determined using the modified Cochrane tool. A narrative synthesis was undertaken. EVIDENCE SYNTHESIS: Overall, 43 studies between 1996 and 2020 were included. LS patients exhibited a 14-fold increased risk of UTUC compared with the general population, which further increased to 75-fold among hMSH2 mutation carriers. Patients younger than 65 yr and patients with personal or family history of LS-related cancers should be referred to molecular testing on tumour specimen and subsequent genetic testing to confirm LS. Newly diagnosed LS patients may benefit from a multidisciplinary management team including gastroenterologist and gynaecologist specialists, while genetic counselling should be recommended to first-degree relatives (FDRs). Compared with sporadic UTUC individuals, LS patients were significantly younger (p = 0.005) and exhibited a prevalent ureteral location (p = 0.01). Radical nephroureterectomy was performed in 75% of patients (5-yr cancer-specific survival: 91%). No consensus on screening protocols for UTUC was achieved: starting age varied between 25-35 and 50 yr, while urinary cytology showed sensitivity of 29% and was not recommended for screening. CONCLUSIONS: Urologists should recognise patients at high risk for LS and address them to a comprehensive diagnostic pathway, including molecular and genetic testing. Newly diagnosed LS patients should be referred to a multidisciplinary team, while genetic counselling should be recommended to FDRs. PATIENT SUMMARY: In this systematic review, we analysed the existing literature focused on upper tract urothelial carcinoma (UTUC) among patients with Lynch syndrome (LS). Our purpose is to provide a comprehensive overview of LS-related UTUC to reduce misdiagnosis and improve patient prognosis.
650    12
$a karcinom z přechodných buněk $x diagnóza $x genetika $x patologie $7 D002295
650    12
$a dědičné nepolypózní kolorektální nádory $x diagnóza $x genetika $x patologie $7 D003123
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory močového měchýře $7 D001749
650    _2
$a urologové $7 D000072178
650    12
$a urologie $7 D014572
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Necchi, Andrea $u University Vita-Salute San Raffaele, Milan, Italy; Department of Medical Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Gómez Rivas, Juan $u Department of Urology, Clinico San Carlos Hospital, Madrid, Spain
700    1_
$a Afferi, Luca $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Martini, Alberto $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Ventimiglia, Eugenio $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Colombo, Renzo $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Gandaglia, Giorgio $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Salonia, Andrea $u University Vita-Salute San Raffaele, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Briganti, Alberto $u University Vita-Salute San Raffaele, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Montorsi, Francesco $u University Vita-Salute San Raffaele, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Mattei, Agostino $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland
700    1_
$a Simeone, Claudio $u Department of Urology, Spedali Civili di Brescia, Brescia, Italy
700    1_
$a Carlo, Maria I $u Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Spiess, Philippe E $u Department of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA
700    1_
$a Moschini, Marco $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
710    2_
$a European Association of Urology Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group, the Global Society of Rare Genitourinary Tumors GSRGT
773    0_
$w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 5, č. 1 (2022), s. 30-41
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34896051 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135632 $b ABA008
999    __
$a ok $b bmc $g 1822850 $s 1170668
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 5 $c 1 $d 30-41 $e 20211209 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace